
James Yu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9678924/publications.pdf Version: 2024-02-01



IAMES YU

#	Article	IF	CITATIONS
1	Prevention and treatment of FGFR inhibitor-associated toxicities. Critical Reviews in Oncology/Hematology, 2020, 155, 103091.	4.4	35
2	A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer. British Journal of Cancer, 2021, 124, 1803-1808.	6.4	20
3	A Phase I Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer. Oncologist, 2020, 25, e1893-e1899.	3.7	16
4	Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib. OncoTargets and Therapy, 2021, Volume 14, 5145-5160.	2.0	14
5	Evaluation and Feedback for Telehealth From Patients and Physicians During the Early Stage of COVID-19 Pandemic Period. Cureus, 2021, 13, e12633.	0.5	6
6	Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies. Expert Opinion on Investigational Drugs, 2021, 30, 451-461.	4.1	6
7	Mutational profiling of myeloid neoplasms associated genes may aid the diagnosis of acute myeloid leukemia with myelodysplasia-related changes. Leukemia Research, 2021, 110, 106701.	0.8	3
8	Adverse Impact of DNA Methylation Regulatory Gene Mutations on the Prognosis of AML Patients in the 2017 ELN Favorable Risk Group, Particularly Those Defined by NPM1 Mutation. Diagnostics, 2021, 11, 986.	2.6	2
9	Adverse overall survival impact of PD-L1 positivity in patients with KRAS G12C mutation is abolished by the immunotherapy. Clinical Lung Cancer, 2021, 22, e856-e858.	2.6	1
10	Bisphosphonate-Induced Acute Orbital Inflammation in a Patient With Underlying Thyroid Ophthalmopathy. Cureus, 2020, 12, e12024.	0.5	1